Benzinga's Small Cap Movers for Monday February 25, 2013
Below are highlights from Benzinga's daily coverage of small cap securities making big moves:
Shares of Venaxis (NASDAQ: APPY), the Castle Rock, CO in vitro diagnostic company, rose 12% Monday on 7 times average volume.
Venaxis was upgraded to Buy from Hold at Canaccord on Monday, with a $7.50 price target.
Venaxis closed at $2.40 on Monday.
EDAP (NASDAQ: EDAP), the Lyon, France designer, developer of the Ablatherm high-intensity focused ultrasound treatment for localized prostate cancer, rose another 25% Monday on 9 times average volume.
EDAP was featured in Benzinga's Small Cap Movers article on Friday.
EDAP closed at $4.09 on Monday.
Shares of Ocean Bio-Chem (NASDAQ: OBCI), the Fort Lauderdale, FL manufacturer, marketer and distributor of a line of appearance and maintenance products for boats, recreational vehicles, automobiles, power sports, outdoor power equipment and motorcycle markets under the Star brite StarTron brands, rose 25% Monday on 65 times average volume.
Ocean Bio-Chem announced Monday, the U.S. EPA approval of Ocean Bio-Chem's new product, Xtrem-A-Cide P®, a broad-spectrum disinfectant that is approved for use as a sanitizer, virucide, tuberculocide, fungicide, algaecide, slimicide and deodorizer.
Ocean Bio-Chem closed at $2.88 on Monday.
The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.